Back to Search
Start Over
Position paper on CDK4/6 inhibitors in early breast cancer
- Source :
- memo - Magazine of European Medical Oncology. 16:135-144
- Publication Year :
- 2023
- Publisher :
- Springer Science and Business Media LLC, 2023.
-
Abstract
- SummaryInhibitors of the cyclin-dependent kinases 4/6 (CDK4/6i) have been practice-changing and are now considered the standard of care in combination with endocrine therapy for the first- or second-line treatment in advanced hormone-receptor-positive, human epidermal growth factor receptor 2‑negative breast cancer. Recently, CDK4/6i have also emerged as an appealing targeted cancer therapy in early breast cancer, however results of large clinical trials are controversial. This position paper summarizes the evidence, and provides guidance for clinical practice.
- Subjects :
- Oncology
Hematology
Subjects
Details
- ISSN :
- 18655076 and 18655041
- Volume :
- 16
- Database :
- OpenAIRE
- Journal :
- memo - Magazine of European Medical Oncology
- Accession number :
- edsair.doi...........b257c1d2b979bac205febbe70c916847